La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Almirall Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Almirall sono diminuiti a un tasso medio annuo di -62.1%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 8.9%. I ricavi sono cresciuti crescere a un tasso medio annuo di 1%.

Informazioni chiave

-62.1%

Tasso di crescita degli utili

-61.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	5.0%
Tasso di crescita dei ricavi	1.0%
Rendimento del capitale proprio	-2.4%
Margine netto	-3.8%
Prossimo aggiornamento sui guadagni	11 Nov 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Sep 07

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Jul 12

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Dec 01

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Jul 14

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Mar 23

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Feb 24

Is Almirall (BME:ALM) Using Too Much Debt?

Nov 01

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Aug 02

Is Almirall (BME:ALM) Using Too Much Debt?

Jul 06

Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden

Mar 23

How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock?

Mar 05

Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 15

Ripartizione dei ricavi e delle spese

Come Almirall guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BME:ALM Ricavi, spese e utili (EUR Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	932	-35	220	0
31 Mar 24	915	-39	214	3
31 Dec 23	899	-38	209	0
30 Sep 23	907	7	209	7
30 Jun 23	898	-11	201	0
31 Mar 23	882	-8	205	3
31 Dec 22	879	4	202	0
30 Sep 22	864	9	207	24
30 Jun 22	856	29	197	0
31 Mar 22	843	-50	190	8
31 Dec 21	837	-41	188	0
30 Sep 21	814	-22	201	-10
30 Jun 21	809	-11	185	0
31 Mar 21	790	55	188	-8
31 Dec 20	814	74	177	0
30 Sep 20	849	63	167	-8
30 Jun 20	872	86	188	0
31 Mar 20	926	121	188	0
31 Dec 19	911	106	189	0
30 Sep 19	858	85	227	9
30 Jun 19	884	88	182	0
31 Mar 19	789	80	209	3
31 Dec 18	811	78	183	0
30 Sep 18	714	-111	176	-10
30 Jun 18	730	-179	196	0
31 Mar 18	687	-293	195	-6
31 Dec 17	677	-304	207	0
30 Sep 17	735	-128	215	5
30 Jun 17	755	-78	214	0
31 Mar 17	821	73	216	5
31 Dec 16	822	75	213	0
30 Sep 16	778	162	230	10
30 Jun 16	743	154	210	0
31 Mar 16	721	111	204	2
31 Dec 15	738	132	201	0
30 Sep 15	783	479	190	-28
30 Jun 15	802	488	244	0
31 Mar 15	842	481	250	-11
31 Dec 14	828	448	274	0
30 Sep 14	868	-13	262	-11
30 Jun 14	849	-32	256	0
31 Mar 14	845	-33	261	0
31 Dec 13	825	-34	250	0

Guadagni di qualità: ALM al momento non è redditizia.

Margine di profitto in crescita: ALM al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ALM non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 62.1% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ALM nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ALM non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 4.5% ).

Rendimento del capitale proprio

ROE elevato: ALM ha un Return on Equity negativo ( -2.36% ), in quanto al momento non è redditizio.

Almirall Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings released

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Second quarter 2023 earnings released

First quarter 2023 earnings released

Recent updates

Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)

Second quarter 2024 earnings released

Almirall, S.A. Reiterates Financial Guidance for Full Year 2024

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price

Insufficient new directors

Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year

Dividend of €0.15 announced

Almirall, S.A. Provides Earnings Guidance for Full Year 2024

Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues

Almirall, S.A., Annual General Meeting, May 10, 2024

These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS misses analyst expectations

Almirall, S.A. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates increase by 15%

Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 29%

Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis

Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022)

Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024

Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?

Now 21% undervalued

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

New minor risk - Shareholder dilution

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released

Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?

Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing

Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million.

New minor risk - Dividend sustainability

Is Almirall (BME:ALM) A Risky Investment?

First quarter 2023 earnings released

Consensus EPS estimates fall by 26%

Almirall, S.A. Reiterates Earnings Guidance for the Year 2023

Estimating The Fair Value Of Almirall, S.A. (BME:ALM)

Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021)

Almirall, S.A., Annual General Meeting, May 05, 2023

Now 20% undervalued after recent price drop

Price target decreased by 7.2% to €11.93

We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt

Now 20% undervalued

An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued

Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023

Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022

Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis

Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study

Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis

Second quarter 2022 earnings: EPS misses analyst expectations

Almirall (BME:ALM) Seems To Use Debt Quite Sensibly

Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index

Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients

Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab

Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis

Now 21% undervalued

Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly

Now 22% undervalued

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Almirall, S.A. Announces Executive Changes

Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp

Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study

Price target decreased to €14.66

Is Almirall (BME:ALM) Using Too Much Debt?

Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe

Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price

Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020)

Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin)

Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults